Abstract
Background Restriction Spectrum Imaging restriction score (RSIrs) is a quantitative biomarker for detecting clinically significant prostate cancer (csPCa). However, the quantitative value of the RSIrs is affected by imaging parameters such as echo time (TE).
Purpose The purpose of the present study is to develop a calibration method to account for differences in echo times and facilitate use of RSIrs as a quantitative biomarker for the detection of csPCa.
Methods This study included 197 consecutive patients who underwent MRI and biopsy examination; 97 were diagnosed with csPCa (grade group ≥ 2). RSI data were acquired three times during the same session: twice at minimum TE∼75ms and once at TE=90ms (TEmin1, TEmin2, and TE90, respectively). A proposed calibration method, trained on patients without csPCa, estimated a linear scaling factor (f) for each of the four diffusion compartments (C) of the RSI signal model. A linear regression model was determined to match C-maps of TE90 to the reference C-maps of TEmin1 within the interval ranging from 95th to 99th percentile of signal intensity within the prostate. RSIrs comparisons were made at 98th percentile within each patient’s prostate.
We compared RSIrs from calibrated TE90 (RSIrsTE90corr) and uncorrected TE90 (RSIrsTE90) to RSIrs from reference TEmin1 (RSIrsTEmin1) and repeated TEmin2 (RSIrsTEmin2). Calibration performance was evaluated with sensitivity, specificity, area under the ROC curve, positive predicted value, negative predicted value, and F1-score.
Results Scaling factors for C1, C2, C3, and C4 were estimated as 1.70, 1.38, 1.03, and 1.19, respectively. In non-csPCa cases, the 98th percentile of RSIrsTEmin2 and RSIrsTEmin1 differed by 0.27±0.86SI (mean±standard deviation), whereas RSIrsTE90 differed from RSIrsTEmin1 by 1.81±1.20SI. After calibration, this bias was reduced to -0.41±1.20SI, representing a 78% reduction in absolute error. For patients with csPCa, the difference was 0.54±1.98SI between RSIrsTEmin2 and RSIrsTEmin1 and 2.28±2.06SI between RSIrsTE90 and RSIrsTEmin1. After calibration, the mean difference decreased to -0.86SI, a 38% reduction in absolute error. At the Youden index for patient-level classification of csPCa (8.94SI), RSIrsTEmin1 has a sensitivity of 66% and a specificity of 72%. Prior to calibration, RSIrsTE90 at the same threshold tended to over-diagnose benign cases (sensitivity 44%, specificity 88%). Post-calibration, RSIrsTE90corr performs more similarly to the reference (sensitivity 71%, specificity 62%).
Conclusion The proposed linear calibration method produces similar quantitative biomarker values for acquisitions with different TE, reducing TE-induced error by 78% and 38% for non-csPCa and csPCa, respectively.
Competing Interest Statement
AMD is a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc., and receives funding through research agreements with General Electric Healthcare. RRP is a consultant for Human Longevity, Inc. She also receives funding through research grants from GE Healthcare and Imagine Scientific to UC San Diego; she has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. She also has an equity interest in CureMetrix. TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, Janssen, and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of the above arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Funding Statement
This work was supported, in part, by the National Institutes of Health (NIH/NIBIB K08EB026503, NIH UL1TR000100), the American Society for Radiation Oncology, the Prostate Cancer Foundation, and the Department of Defense (DOD/CDMRP PC220278).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted under the approval of the institutional review board at UC San Diego (IRB 210213) with a waiver of consent for prospective collection of RSI at multiple TEs.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos